Navigation Links
BioCryst Updates Peramivir Clinical Development Plan
Date:1/23/2008

150mg and 300mg doses in the Phase II trial, the Company also believes it is prudent to evaluate whether doses higher than 300mg provide additional efficacy. The Company has been limited in evaluating doses higher than 300mg due to the concentration of the formulation used in the Phase II trial. Alternative formulations are being developed, and should be available, that permit evaluation of a single dose higher than 300mg. BioCryst is now planning to initiate a Phase II clinical trial that will evaluate the 300mg dose and a higher dose of peramivir later this year. As a result, BioCryst will not continue to pursue a pivotal Phase III program for i.m. peramivir in the current influenza season.

"All of these analyses have reinforced our belief that adequate and consistent systemic exposure to peramivir is critical to demonstrate the clinical benefits of peramivir," said Jon P. Stonehouse, President and CEO of BioCryst. "This strategy allows us to test a higher dose, utilize a new formulation and make the adjustments in needle-length, all in one study. This strategy gives us confidence that we can maximize the likelihood of achieving a successful result."

After discussions between BioCryst and HHS, the Company believes that peramivir remains an important potential therapy for both seasonal influenza and pandemic preparedness. The key elements of the HHS contract remain the same. The contract amount is $102.6M and the term is four years (concluding December 31, 2010). The development plan for peramivir has changed from that outlined in the original proposal to HHS. HHS has indicated that they will fund certain elements of the revised program, including the ongoing Phase II i.v. study in hospitalized subjects, planning and conduct of the planned Phase II i.m. study, manufacturing and toxicology. Each of these elements has specific HHS funding limits. Any costs in excess of these limits will be the responsibility of BioCryst. The Company anticipates that th
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
2. BioCryst Provides Forodesine HCl Update
3. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
4. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
7. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
8. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... YORK , July 29, 2014 /PRNewswire-iReach/ -- ... the basis of products, methods, applications, end users, ... highest growth in the microbial identification market. This ... consumable costs (per test) and the time required ... and continuous technological advancements. Furthermore, genotypic methods have ...
(Date:7/29/2014)... , July 29, 2014 Regado Biosciences, ... focused on the Phase 3 clinical development of Revolixys™ ... antithrombotic drug system, today announced that it will hold ... Aug. 12, 2014, at 8:30 a.m. EDT to discuss ... Interested participants and investors may access the ...
(Date:7/29/2014)... , July 29, 2014  Landauer, Inc. (NYSE: ... environmental radiation measurement and monitoring, outsourced medical physics services ... results for the fiscal third quarter 2014 after the ... The Company will host a conference call for ... Central Time (10 a.m. Eastern Time). Investors may access ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2
... International, Inc. (Nasdaq: HTWR ; ASX: HIN), ... technologies that are revolutionizing the treatment of advanced heart ... to make an investor presentation at the UBS 2010 ... 12:30 pm EDT.  The conference will be held September ...
... KING OF PRUSSIA, Pa., Sept. 15 ... into a strategic alliance with Campbell Informatics, an integrated ... alliance of Tunnell, a leading life sciences industry consultancy, ... life sciences manufacturers, suppliers and regulators, is designed to ...
Cached Medicine Technology:HeartWare to Present at the UBS 2010 Global Life Sciences Conference 2Tunnell Consulting Forms Strategic Alliance With Ireland-Based Campbell Informatics 2
(Date:7/30/2014)... Seattle, WA (PRWEB) July 30, 2014 According ... by Vkool.com, this is a comprehensive guide that teaches people ... a few weeks. The book uncovers to readers the horrible ... writes in its review that inside this book, people will ... such as inflammation, asthma, and nasal infections. , Nasal ...
(Date:7/30/2014)... 30, 2014 pMD, the leading ... launched an Observation Result (ORU) interface to streamline ... cardiology customers are using the ORU interface to ... test interpretations for electrocardiograms, echocardiograms, and stress tests. ... hospital, the cardiology system produces electronic data for ...
(Date:7/29/2014)... July 29, 2014 Paul Mata, CEO of ... More Money in 30 Days” E-book. The e-book includes a ... to make extra cash. Examples include downloading and utilizing specific ... websites that help people monetize the assets they didn't know ... items they can find in their garage. , After ...
(Date:7/29/2014)... 2014 Dignity Sciences Limited, a privately ... a Phase I trial with DS107G, an oral formulation ... was a randomized, placebo-controlled, double-blind, single-ascending and multiple dose ... and effect of food on DS107G in healthy subjects. ... of DGLA following both single and multiple oral doses ...
(Date:7/29/2014)... Use of electroacupuncture (EA) a form of ... between pairs of acupuncture needles produces significant ... little as eight weeks for early stage breast ... use of aromatase inhibitors (AIs) to treat breast ... examining the intervention led by researchers at the ...
Breaking Medicine News(10 mins):Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3
... of Women’s Heart Health by setting up 100 chest pain ... clinics will be spread across the country. // ... Hospitals, spoke of Apollo’s plan to set up chest pain ... (ACE), as it is called, will comprise of the chest ...
... Eating a healthy die is very essential to maintain ... rich in nutrients such as fruits and vegetables along ... prevents chronic diseases like cancer, diabetes, obesity and hypertension. ... present in lean meats, eggs, beans, nuts and they ...
... about AIDS/HIV, the Rotarians of Malda and the district ... program// ('One step for awareness about HIV-AIDS') in the ... ,The local barbers, under the guidance of the organizing ... was conducted at Rotary Bhawan. The heath officials projected ...
... that whole-grain foods keep triglycerides in their limits and keep ... Agricultural Research// Service scientists in California provides the know-how as ... chemist Nancy L. Keim, "Lipoproteins are the body's means of ... to fatty tissue, where they're stored as reserves.” ,It ...
... tight spot after it was suggested that , one ... be poor cabin air quality//.DVT is not caused by mere ... who suggest that cabin air quality may also play a ... journal seems to throw up plausible risk factors risk factors. ...
... a major role in reducing the bad cholesterol. For example ... Canadian researchers said that by combining these food substances one ... such diet as they are at a higher risk of ... the bad cholesterol (LDL) as effectively as a commonly prescribed ...
Cached Medicine News:Health News:A Complete Diet for Kids 2Health News:Fat fighters’: Whole-grain foods’: under the microsco 2Health News:Poor Quality of Cabin Air in the Plane Can Cause DVT, After A Long Flight 2Health News:Choose Foods That Keep Bad Cholesterol at Bay 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: